Nu Skin Enterprises (NUS) posts $5.14 EPS loss, sees 2026 revenue down up to 14%

Rhea-AI Filing Summary

Nu Skin Enterprises reported weak second-quarter 2026 results heavily affected by non-cash charges. Revenue was $320.1 million, down 17.1% from $386.1 million, with a 1.0% FX headwind. Customers declined 14% to 660,037, Paid Affiliates fell 8%, and Sales Leaders decreased 9%, indicating broad-based volume pressure across regions.

GAAP diluted EPS was a loss of $(5.14), driven largely by a $78.9 million impairment charge and a substantial valuation allowance on deferred tax assets, producing an effective tax rate of (295.4)%. On a non-GAAP basis, EPS was $0.20, versus $0.43 a year earlier, and operating margin was 6.1% excluding impairment, compared with 8.0%.

For full-year 2026, the company now guides revenue to $1.28–$1.35 billion, a 14%–9% decline, and GAAP EPS of $(4.90)–$(4.73), or $0.70–$0.90 on an adjusted basis. Q3 2026 revenue is expected at $310–$340 million with adjusted EPS of $0.10–$0.20, while management continues rolling out the Prysm iO platform and preparing for an India launch.

Positive

• Adjusted EPS of $0.20 remained positive in Q2 2026, and adjusted operating margin was 6.1%, showing underlying profitability despite large non-cash impairment and tax charges.
• The company reaffirmed a positive adjusted EPS outlook of $0.70–$0.90 for full-year 2026, indicating expectations for ongoing earnings on a non-GAAP basis.
• Nu Skin maintained shareholder returns with $2.9 million in dividend payments during Q2 2026 and still has $137.3 million remaining under its stock repurchase authorization.

Negative

• Q2 2026 revenue declined 17.1% year over year to $320.1 million, with broad decreases across all Nu Skin and Rhyz segments.
• GAAP diluted EPS swung to a $(5.14) loss from $0.43, driven by a $78.9 million impairment and a large valuation allowance on deferred tax assets.
• Total Customers fell 14% to 660,037, with declines across most regions, while Paid Affiliates and Sales Leaders declined 8% and 9%, respectively, signaling weakening field and customer engagement.
• Full-year 2026 guidance implies a 14%–9% revenue decline to $1.28–$1.35 billion, pointing to continued top-line pressure.
• Cash and cash equivalents decreased from $238.6 million at December 31, 2025 to $189.6 million at June 30, 2026, while retained earnings fell from $1.86 billion to $1.61 billion.

Filing Explained

At June 30, cash and equivalents were reported alongside debt; no repurchases occurred.

This August 10 Form 8-K furnishes Nu Skin’s results for the three and six months ended June 30, 2026, so the results are reported rather than prospective. For existing common holders, the filing reports $2.9 million of dividend payments, no second-quarter stock repurchases, and $137.3 million of repurchase authorization remaining.

The $137.3 million figure is authorization remaining, not a reported repurchase or cash payment.

At June 30, 2026, the balance sheet reported cash and equivalents, current debt, and long-term debt.

Compared with December 31, 2025, cash and equivalents and total stockholders’ equity both declined.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Q2 2026 Revenue: $320.1 million Q2 2026 GAAP Diluted EPS: $(5.14) Q2 2026 Adjusted EPS: $0.20 +5 more

8 metrics

Q2 2026 Revenue $320.1 million Three months ended June 30, 2026; down 17.1% year over year

Q2 2026 GAAP Diluted EPS $(5.14) Includes non-cash impairment and tax charges

Q2 2026 Adjusted EPS $0.20 Excludes non-cash impairment and non-cash tax charges; prior year $0.43

Impairment Expense Q2 2026 $78.875 million Impairment expenses in the quarter ended June 30, 2026

Total Customers Q2 2026 660,037 Down 14% versus the three months ended June 30, 2025

Cash and Cash Equivalents $189.643 million Balance as of June 30, 2026

2026 Revenue Guidance $1.28–$1.35 billion Represents a 14%–9% decline from 2025 revenue

Q2 2026 Dividend Payments $2.9 million Dividends paid to stockholders in the quarter

Key Terms

constant-currency revenue change, operating margin, valuation allowance on deferred tax assets, non-GAAP financial measures, +1 more

5 terms

constant-currency revenue change financial

"The following table sets forth revenue... and Constant- Currency Change"

operating margin financial

"Operating margin, excluding certain charges was 6.1%"

Operating margin shows how much profit a company makes from its core business activities after paying for costs like wages and materials. It’s useful because it tells you how efficiently a company is running—higher margins mean it keeps more money from each dollar of sales, which can indicate better management or stronger products.

valuation allowance on deferred tax assets financial

"Impact of valuation allowance on deferred tax assets"

A valuation allowance on deferred tax assets is an accounting reserve a company sets up when it doubts it will be able to use tax benefits it has recorded, such as past losses or tax credits, to reduce future taxes. Think of it like marking down the value of a coupon because you’re unlikely to use it; it matters to investors because increasing the allowance can reduce reported profits and suggest weaker future cash tax savings and lower financial strength.

non-GAAP financial measures financial

"Non-GAAP Financial Measures Constant-currency revenue change is a non-GAAP financial measure"

Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.

impairment charges financial

"Impairment charges of 78,875 affected earnings per share"

Impairment charges are one-time accounting write-downs taken when a company decides an asset — like a factory, brand, patent, or investment — is worth less than it was recorded for. Like marking down the price of a damaged item on a store shelf, they reduce reported profits and the asset’s book value; investors watch them because they can signal lasting business problems or change future earnings and balance-sheet strength.

Earnings Snapshot

Revenue Q2 2026: $320.1 million · Guidance included

quarter and six months ended June 30, 2026

Revenue Q2 2026 $320.1 million -17.1% vs prior-year quarter

GAAP Diluted EPS Q2 2026 $(5.14) down from $0.43 in prior-year quarter

Adjusted EPS Q2 2026 $0.20 down from $0.43 in prior-year quarter

Total Customers Q2 2026 660,037 -14% vs prior-year quarter

2026 Revenue Guidance $1.28–$1.35 billion represents a 14%–9% decline from 2025

Guidance

For Q3 2026, expected revenue is $310–$340 million with GAAP EPS of $0.00–$0.09 and adjusted EPS of $0.10–$0.20; for full-year 2026, revenue is guided to $1.28–$1.35 billion with GAAP EPS of $(4.90)–$(4.73) and adjusted EPS of $0.70–$0.90.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/10/2026 - 04:16 PM Accepted by SEC EDGAR 08/10/2026 - 04:15 PM Learn about SEC filing dates

FAQ

How did Nu Skin (NUS) perform financially in Q2 2026?

Nu Skin reported Q2 2026 revenue of $320.1 million, down 17.1% year over year, and a GAAP diluted EPS loss of $(5.14). Excluding non-cash impairment and tax charges, adjusted EPS was $0.20, down from $0.43 in the prior-year quarter.

What guidance did Nu Skin (NUS) provide for full-year 2026?

For 2026, Nu Skin expects revenue of $1.28–$1.35 billion, a 14%–9% decline versus 2025, and GAAP EPS of $(4.90)–$(4.73). On an adjusted basis, the company projects EPS of $0.70–$0.90 for the full year.

What are Nu Skin’s (NUS) expectations for Q3 2026?

For Q3 2026, Nu Skin projects revenue between $310 million and $340 million, a 15%–7% decline year over year, with FX pressure of about 3%–2%. It expects GAAP EPS of $0.00–$0.09 and adjusted EPS of $0.10–$0.20.

How did Nu Skin’s (NUS) customer and affiliate base change in Q2 2026?

Total Customers decreased 14% to 660,037 in Q2 2026. Paid Affiliates fell 8% to 120,291, and Sales Leaders declined 9% to 26,998. Most geographic regions reported lower customer counts compared with the prior-year quarter.

What major charges affected Nu Skin’s (NUS) Q2 2026 results?

Results were significantly impacted by a $78.9 million impairment charge and a valuation allowance on deferred tax assets, contributing to a $(5.14) GAAP EPS loss and an effective tax rate of (295.4)% for the quarter.

How did Nu Skin’s (NUS) segment revenues perform in Q2 2026?

Total Nu Skin segment revenue was $271.2 million, down 15.5%, with declines across all regions, including Americas down 18.1% and South Korea down 24.8%. Rhyz revenue fell 25.0% to $48.9 million.

What is Nu Skin’s (NUS) cash and debt position as of June 30, 2026?

As of June 30, 2026, Nu Skin had $189.6 million in cash and cash equivalents and $215.0 million of total debt (current and long term). Total assets were $1.12 billion and stockholders’ equity was $542.7 million.

false000102156100010215612026-08-102026-08-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

August 10, 2026

Date of Report (Date of earliest event reported)

NU SKIN ENTERPRISES, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-12421		87-0565309
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

75 West Center Street

Provo, Utah 84601

(Address of principal executive offices and zip code)

(801) 345-1000

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A Common Stock, $.001 par value	NUS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 10, 2026, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three- and six-month periods ended June 30, 2026, and certain other information. A copy of the press release is attached as Exhibit 99.1 to this report.

The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.
99.1	Nu Skin Enterprises’ press release dated August 10, 2026, regarding financial results for the three- and six-month periods ended June 30, 2026.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NU SKIN ENTERPRISES, INC.

(Registrant)

/s/ Chelsea K. Lantz

Chelsea K. Lantz

Chief Financial Officer

Date: August 10, 2026

Exhibit 99.1

FOR IMMEDIATE RELEASE

Nu Skin Enterprises Reports Second Quarter Results

PROVO, Utah — Aug. 10, 2026 — Nu Skin Enterprises Inc. (NYSE: NUS) today announced second quarter results.

Executive Summary

Q2 2026 vs. Prior-year Quarter

Revenue			$320.1 million; (17.1)% •          (1.0)% FX impact or $(4.0) million
Earnings Per Share (EPS)			$(5.14) or $0.20 excluding non-cash impairment and non-cash tax charges compared to $0.43
Customers			660,037; (14)%
Paid Affiliates			120,291; (8)%
Sales Leaders			26,998; (9)%

“We continue to make progress toward our long-term strategy with the continued rollout of Prysm iO and preparations for the formal launch of India,” said Ryan Napierski, Nu Skin president and CEO. “As these initiatives are taking hold, we are incorporating valuable learnings to strengthen our plans moving forward. At the same time, we are re-aligning our organizational resources to better position the business to drive sustainable, long-term value for our shareholders.”

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results page 2

Q2 2026 Year-over-year Operating Results

Revenue			$320.1 million compared to $386.1 million •          (1.0)% FX impact or $(4.0) million
Gross Margin			68.2% compared to 68.8% •          Nu Skin business was 77.7% compared to 77.5%
Selling Expenses			33.7% compared to 33.2% •          Nu Skin business was 39.8% compared to 40.0%
G&A Expenses			28.4% compared to 27.6%
Operating Margin			(18.5)% or 6.1% excluding non-cash impairment charge compared to 8.0%
Interest Expense			$3.3 million compared to $2.5 million
Other Income (Expense)			$(0.5) million compared to $(0.8) million
Income Tax Rate			(295.4)% or 36.6% excluding non-cash tax charge compared to 23.0%
EPS			$(5.14) or $0.20 excluding non-cash impairment and non-cash tax charges compared to $0.43

Stockholder Value

Dividend Payments			$2.9 million
Stock Repurchases			$0.0 million •          $137.3 million remaining in authorization

Q3 and Full-year 2026 Outlook

Q3 2026 Revenue			$310 to $340 million; (15)% to (7)% •          Approximately (3) to (2)% FX impact
Q3 2026 EPS			$0.00 to $0.09 or $0.10 to $0.20 on an adjusted basis
2026 Revenue			$1.28 to $1.35 billion;  (14)% to (9)% •          Approximately (1)% FX impact
2026 EPS			($4.90) to ($4.73) or $0.70 to $0.90 on an adjusted basis

“We delivered adjusted earnings per share near the midpoint of our guidance, reflecting our ongoing focus on profitability and disciplined execution,” said Chelsea Lantz, interim chief financial officer. “Based on our first-half performance and outlook for the rest of the year, we are updating our annual guidance to revenue of $1.28 billion to $1.35 billion and adjusted earnings per share of $0.70 to $0.90. For the third quarter, we expect revenue between $310 million and $340 million, with adjusted earnings per share in the range of $0.10 to $0.20.”

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results page 3

Conference Call

The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through Aug. 24, 2026.

About Nu Skin Enterprises Inc.

Nu Skin Enterprises Inc. (NYSE: NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company’s products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal care and wellness products. Rhyz is the strategic investment arm of Nu Skin Enterprises, formed in 2018 consisting of synergistic consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.

Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the company’s performance, growth, initiatives, shareholder value, Prysm launch and its timing, and India expansion; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “become,” “drive,” “project,” “outlook,” “guidance,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

• any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;

• risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;

• economic conditions and events globally;

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results page 4

• the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets, and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets;

• competitive pressures in the company’s markets;

• risk that epidemics or other crises, as well as any related disruptions, could negatively impact our business;

• adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;

• political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;

• uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;

• risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;

• uncertainties regarding the future financial performance of the businesses the company has acquired;

• risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies; and

• regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements.

The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.

Earnings per share, operating margin, and income tax rate, each excluding impairment charges, tax charges, and/or other charges, also are non-GAAP financial measures.

• Impairment charges and the tax charge incurred in the second quarter of 2026 are not part of the ongoing operations of our underlying business; and

• The other charges incurred in connection with certain corporate actions, as described in the footnotes to the non-GAAP reconciliation tables below, are not part of our ongoing operations.

The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these items facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share, gross margin, operating margin, income tax rate and revenue growth rate calculated under GAAP, below.

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results page 5

The following table sets forth revenue for the three-month periods ended June 30, 2026, and 2025 for each of our reportable segments (U.S. dollars in thousands):

		Three Months Ended June 30,												Constant- Currency Change
								2026				2025						Change
Nu Skin
Americas		$	59,763			$	72,946				(18.1	)%			(15.8	)%
Mainland China			45,956				53,224				(13.7	)%			(18.7	)%
Southeast Asia/Pacific			43,257				50,834				(14.9	)%			(16.3	)%
Japan			38,143				44,550				(14.4	)%			(5.5	)%
Europe & Africa			32,317				37,328				(13.4	)%			(15.2	)%
Hong Kong/Taiwan			26,074				27,527				(5.3	)%			(3.6	)%
South Korea			25,620				34,068				(24.8	)%			(19.0	)%
Nu Skin Other			79				427				(81.5	)%			(81.5	)%
Total Nu Skin			271,209				320,904				(15.5	)%			(14.2	)%
Rhyz
Manufacturing			46,369				60,400				(23.2	)%			(23.2	)%
Rhyz Other			2,534				4,834				(47.6	)%			(47.6	)%
Total Rhyz			48,903				65,234				(25.0	)%			(25.0	)%
Total		$	320,112			$	386,138				(17.1	)%			(16.1	)%

The following table sets forth revenue for the six-month periods ended June 30, 2026, and 2025 for each of our reportable segments (U.S. dollars in thousands):

		Six Months Ended June 30,												Constant- Currency Change
								2026				2025						Change
Nu Skin
Americas		$	117,581			$	142,004				(17.2	)%			(14.2	)%
Mainland China			91,104				100,999				(9.8	)%			(14.6	)%
Southeast Asia/Pacific			88,731				103,006				(13.9	)%			(16.5	)%
Japan			77,882				87,315				(10.8	)%			(4.9	)%
Europe & Africa			63,535				70,349				(9.7	)%			(15.0	)%
Hong Kong/Taiwan			53,531				55,974				(4.4	)%			(4.8	)%
South Korea			50,949				66,583				(23.5	)%			(20.2	)%
Nu Skin Other			(155	)			956				(116.2	)%			(116.2	)%
Total Nu Skin			543,158				627,186				(13.4	)%			(13.4	)%
Rhyz
Manufacturing			91,294				115,690				(21.1	)%			(21.1	)%
Rhyz Other			6,268				7,752				(19.1	)%			(19.1	)%
Total Rhyz			97,562				123,442				(21.0	)%			(21.0	)%
Total		$	640,720			$	750,628				(14.6	)%			(14.6	)%

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results page 6

The following tables provide information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended June 30, 2026 and 2025.

		Three Months Ended June 30,								Change
								2026						2025
Customers
Americas			183,757				240,477				(24	)%
Mainland China			103,891				117,325				(11	)%
Southeast Asia/Pacific			69,354				72,814				(5	)%
Japan			100,849				105,961				(5	)%
Europe & Africa			111,332				126,146				(12	)%
Hong Kong/Taiwan			36,549				41,371				(12	)%
South Korea			54,305				67,313				(19	)%
Total Customers			660,037				771,407				(14	)%
Paid Affiliates
Americas			27,337				28,827				(5	)%
Mainland China			18,736				19,399				(3	)%
Southeast Asia/Pacific			17,677				21,092				(16	)%
Japan			19,018				19,605				(3	)%
Europe & Africa			13,307				15,320				(13	)%
Hong Kong/Taiwan			9,390				9,570				(2	)%
South Korea			14,826				16,986				(13	)%
Total Paid Affiliates			120,291				130,799				(8	)%
Sales Leaders
Americas			5,041				5,971				(16	)%
Mainland China			5,899				5,790				2	%
Southeast Asia/Pacific			3,631				4,126				(12	)%
Japan			5,782				5,882				(2	)%
Europe & Africa			2,216				2,695				(18	)%
Hong Kong/Taiwan			1,858				2,063				(10	)%
South Korea			2,571				3,066				(16	)%
Total Sales Leaders			26,998				29,593				(9	)%

• “Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our salesforce who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.

• “Paid Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.

• “Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter.

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results page 7

NU SKIN ENTERPRISES, INC.

Consolidated Statements of Income (Unaudited)

(U.S. dollars in thousands, except per share amounts)

		Three Months Ended June 30,								Six Months Ended June 30,
								2026										2025				2026				2025
Revenue		$	320,112			$	386,138			$	640,720			$	750,628
Cost of sales			101,787				120,405				207,932				237,934
Gross profit			218,325				265,733				432,788				512,694
Operating expenses:
Selling expenses			107,922				128,228				217,976				246,774
General and administrative expenses			90,847				106,725				189,391				219,929
Impairment expenses			78,875				-				80,714				25,114
Total operating expenses			277,644				234,953				488,081				491,817
Operating income (loss)			(59,319	)			30,780				(55,293	)			20,877
Interest expense			3,322				2,526				7,572				5,809
Gain on sale of business			-				-				-				176,162
Other income (expense), net			(534	)			(843	)			2,289				(29,218	)
Income (loss) before provision for income taxes			(63,175	)			27,411				(60,576	)			162,012
Provision for income taxes			186,623				6,292				187,386				33,378
Net income (loss)		$	(249,798	)		$	21,119			$	(247,962	)		$	128,634
Net income (loss) per share (Note 7):
Basic		$	(5.14	)		$	0.43			$	(5.12	)		$	2.59
Diluted		$	(5.14	)		$	0.43			$	(5.12	)		$	2.59
Weighted-average common shares outstanding (000s):
Basic			48,596				49,441				48,400				49,601
Diluted			48,596				49,499				48,400				49,748

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results page 8

NU SKIN ENTERPRISES, INC.

Consolidated Balance Sheets (Unaudited)

(U.S. dollars in thousands)

		June 30, 2026				December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents		$	189,643			$	238,630
Current investments			1,743				1,211
Accounts receivable, net			48,902				39,544
Inventories, net			191,497				178,643
Prepaid expenses and other			76,364				89,670
Total current assets			508,149				547,698
Property and equipment, net			379,550				377,168
Operating lease right-of-use assets			65,442				74,021
Goodwill			4,750				83,625
Other intangible assets, net			37,884				42,614
Other assets			125,755				280,187
Total assets			1,121,530				1,405,313
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	37,711			$	26,183
Accrued expenses			198,636				217,551
Current portion of long-term debt			20,000				20,000
Total current liabilities			256,347				263,734
Operating lease liabilities			50,075				57,640
Long-term debt			193,664				204,187
Other liabilities			78,705				74,512
Total liabilities			578,791				600,073
Commitments and contingencies (Notes 6 and 12)
Stockholders’ equity:
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued			91				91
Additional paid-in capital			612,412				635,994
Treasury stock, at cost – 41.9 million and 42.4 million shares			(1,558,183	)			(1,575,059	)
Accumulated other comprehensive loss			(118,152	)			(116,105	)
Retained earnings			1,606,571				1,860,319
Total stockholders' equity			542,739				805,240
Total liabilities and stockholders’ equity		$	1,121,530			$	1,405,313

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results page 9

NU SKIN ENTERPRISES, INC.

Reconciliation of Operating Margin Excluding Certain Charges to GAAP Operating Margin

(in thousands, except for per share amounts)

		Three months ended June 30,								Six months ended June 30,
		2026				2025				2026				2025
Operating Income		$	(59,319	)		$	30,780			$	(55,293	)		$	20,877
Impact of inventory write-off			-				-				3,116				-
Impact of other charges(1)			-				-				2,643				7,966
Impact of impairment			78,875				-				80,714				25,114
Adjusted operating income		$	19,556			$	30,780			$	31,180			$	53,957
Operating margin			(18.5	)%			8.0	%			(8.6	)%			2.8	%
Operating margin, excluding certain charges			6.1	%			8.0	%			4.9	%			7.2	%
Revenue		$	320,112			$	386,138			$	640,720			$	750,628

(1) Other charges for the first quarter of 2026 consist of $1.0 million related to the wind down of the separate BeautyBio business and $1.6 million of other employee severance charges. Other charges for the first quarter of 2025 consist of expenses incurred in connection with the Mavely sale, including $2.7 million of transaction bonuses for certain employees and $5.2 million of equity compensation as a result of the vesting of the Mavely profits interest units.

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results page 10

NU SKIN ENTERPRISES, INC.

Reconciliation of Effective Tax Rate Excluding Impact of Certain Charges to GAAP Effective Tax Rate

(in thousands, except for per share amounts)

		Three months ended June 30,								Six months ended June 30,
		2026				2025				2026				2025
Provision (benefit) for income taxes		$	186,623			$	6,292			$	187,386			$	33,378
Impact of inventory write-off on provision for income taxes			-				-				1,065				-
Impact of other charges(1) on provision for income taxes			-				-				903				725
Impact of impairment on provision for income taxes			(13,370	)			-				(12,741	)			5,433
Impact of gain on Mavely sale on provision for income taxes			-				-				-				(31,104	)
Impact of gain on unrealized investment loss on provision for income taxes			-				-				-				6,074
Impact of valuation allowance on deferred tax assets			(167,505	)			-				(167,505	)			-
Provision for income taxes, excluding impact of certain charges		$	5,748			$	6,292			$	9,108			$	14,506
Income before provision for income taxes			(63,175	)			27,411				(60,576	)			162,012
Impact of inventory write-off			-				-				3,116				-
Impact of other charges(1)			-				-				2,643				7,966
Impact of impairment expense:			78,875				-				80,714				25,114
Impact of gain on Mavely sale			-				-				-				(176,162	)
Impact of unrealized investment loss			-				-				-				28,077
Income before provision for income taxes, excluding impact certain charges		$	15,700			$	27,411			$	25,897			$	47,007
Effective tax rate			(295.4	)%			23.0	%			(309.3	)%			20.6	%
Effective tax rate, excluding impact of certain charges			36.6	%			23.0	%			35.2	%			30.9	%

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results page 11

NU SKIN ENTERPRISES, INC.

Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share

(in thousands, except for per share amounts)

		Three months ended June 30,								Six months ended June 30,
		2026				2025				2026				2025
Net income		$	(249,798	)		$	21,119			$	(247,962	)		$	128,634
Impact of Inventory write-off
Inventory write-off			-				-				3,116				-
Tax impact			-				-				(1,065	)			-
Impact of other charges
Other charges			-				-				2,643				7,966
Tax impact			-				-				(903	)			(725	)
Impact of impairment
Impairment charges			78,875				-				80,714				25,114
Tax impact			13,370				-				12,741				(5,433	)
Impact of Mavely sale
Mavely sale			-				-				-				(176,162	)
Tax impact			-				-				-				31,104
Impact of unrealized investment loss
Unrealized investment loss			-				-				-				28,077
Tax impact			-				-				-				(6,074	)
Impact of valuation allowance on deferred tax assets			167,505				-				167,505				-
Adjusted net income		$	9,952			$	21,119			$	16,789			$	32,501
Diluted earnings per share		$	(5.14	)		$	0.43			$	(5.12	)		$	2.59
Diluted earnings per share, excluding impact of certain charges		$	0.20			$	0.43			$	0.35			$	0.65
Weighted-average common shares outstanding (000)			48,596				49,499				48,400				49,748

Nu Skin Enterprises Reports Second Quarter 2026 Financial Results page 12

NU SKIN ENTERPRISES, INC.

Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share

		Three months ended September 30, 2026								Year ended December 31, 2026
		Low end				High end				Low end				High end
Earnings Per Share		$	0.00			$	0.09			$	(4.90	)		$	(4.73	)
Impact of inventory write-off
Inventory write-off			-				-				0.06				0.06
Tax impact			-				-				(0.02	)			(0.02	)
Impact of other charges
Other charges(2)			0.10				0.10				0.15				0.15
Tax impact			(0.02	)			(0.02	)			(0.04	)			(0.04	)
Impact of impairment:
Impairment charges			-				-				1.67				1.67
Tax impact			-				-				0.26				0.26
Impact of valuation allowance on deferred tax assets			0.02				0.03				3.52				3.55
Adjusted EPS		$	0.10			$	0.20			$	0.70			$	0.90

(2) We are currently anticipating other charges for the third quarter of 2026 of approximately $5 million in cash-based transition cost. Other charges for the first quarter of 2026 consist of $1.0 million related to the wind down of the separate BeautyBio business and $1.6 million of other employee severance charges.

# # #

CONTACTS:

Media: media@nuskin.com, (801) 345-6397

Investors: investorrelations@nuskin.com, (801) 345-3577

Filing Exhibits & Attachments

4 documents

Press Releases

• EX-99.1 PRESS RELEASE DATED AUGUST 10, 2026 653.5 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 21.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 15.7 KB